Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Pete_Lutwyche
|
| gptkbp:collaboratedWith |
gptkb:Moderna
gptkb:BioNTech |
| gptkbp:focusesOn |
drug delivery
RNA therapeutics |
| gptkbp:foundedYear |
2018
|
| gptkbp:hasPatent |
LNP delivery systems
|
| gptkbp:headquartersLocation |
gptkb:Vancouver,_Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Genevant Sciences
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:involvedIn |
COVID-19 vaccine technology
|
| gptkbp:operatesIn |
gptkb:Canada
gptkb:United_States |
| gptkbp:parentCompany |
gptkb:Roivant_Sciences
gptkb:Arbutus_Biopharma |
| gptkbp:specializesIn |
lipid nanoparticle (LNP) technology
|
| gptkbp:website |
https://genevant.com/
|
| gptkbp:bfsParent |
gptkb:BioNTech
gptkb:Roivant_Sciences |
| gptkbp:bfsLayer |
5
|